Clear Water from Pharmaceuticals – CWPharma

Leading organisations:
Environment Institute (Finland), County administrative board (Sweden), Environmental Research Centre (Estonia), Berlin Center for Competence of Water (Germany), Aarhus University (Denmark), Kalundborg Utility (Denmark), Technical facility Linköping (Sweden), Medicines Agency (Finland), Helsinki Region Environmental Services Authority (Finland), Institute of Environmental Protection - National Research Institute (Poland), Institute for Aquatic Ecology (Latvia), Environment, Geology, and Meteorology Centre (Latvia), Waterworks Association (Estonia), Association for Water, Wastewater, and Waste (Germany), and Environment Agency (Germany)


Geographic Area:
Baltic Sea Region


1) To give tools and recommendations to policy makers, authorities and municipalities on the best ways to reduce emissions of active pharmaceutical ingredients (APIs) in the Baltic Sea Region, 2) To fill the gaps of knowledge identified in, e.g. the status report of UNESCO and HELCOM on pharmaceuticals in the Baltic Sea (2017), 3) To increase the awareness of policy-makers, regulators and permitting authorities on environmental risks, implementation of the emission reduction schemes, and eventually decreasing the emissions of APIs into the Baltic Sea Region environment.

Target audience:
Environmental experts, Health Professionals, Hospitals/health system stakeholders, Local governments, National/Local decision and policy makers, Patients, Scientists, Staff of wastewater treatment plants, Waste/water treatment providers, and Water/waste service providers

Area of interest:
Occurrence of pharmaceuticals in the environment, Pharmaceutical consumption by humans, Pharmaceutical waste & waste management, Prescription practices, Risks to ecosystems, Risks to human health, Unused/expired pharmaceutical disposal practices, Wastewater, and Water treatment technologies


1) Screening of a wide range of APIs in six river basin districts to get a more complete picture of sources, emissions and environmental concentrations of APIs, 2) Assessment of the overall emissions of APIs and their impact on the environment in the BSR based on the data from case studies and literature, 3) Evaluation of different emission reduction measures: advanced municipal wastewater treatment, improved take-back schemes and disposal for unused medicines, dissemination of environmental data on pharmaceutical products, and environmental permitting of pharmaceutical plants, 4) Promotion of the best existing practices of the partner countries.

Communication material:

Return to search form.

HCWH Europe gratefully acknowledges the financial support of the European Commission (EC)’s LIFE+ programme, the Federal Ministry for the Environment, Nature Conservation, and Nuclear Safety (BMU) Germany, and the German Environment Agency (UBA). HCWH Europe is solely responsible for the content of this project and related materials. The views expressed do not reflect the official views of the EC, BMU, or UBA.